CAMBRIDGE, Mass, Sept. 18, 2023 /PRNewswire/ — Implicity, a leader in remote patient monitoring (RPM) and cardiac data management solutions, announced today that co-founder and CEO Arnaud Rosier, MD, PhD, has been selected to participate in a panel discussion at the upcoming HRX 2023 Digital Health Event in Seattle, WA. The discussion, AI-aided Remote Interventions – Will […]
Other News
CardiaCare Completes Seed Extension Raise to Support Clinical Pilot Studies
REHOVOT, Israel, Sept. 18, 2023 /PRNewswire/ — CardiaCare, a medical device company developing a breakthrough wearable technology for detecting, monitoring, and non-invasively treating cardiac arrhythmias using drug-free neuromodulation, recently closed an over-subscribed Seed Extension round. The financing was led by Solardis Health Ventures and supports efforts to expand the technology’s clinical program for […]
Field Medical, Inc. Announces Oversubscribed Seed Round to Advance Next-Generation Cardiac Ablation Technology
CARDIFF-BY-THE-SEA, Calif., Sept. 18, 2023 /PRNewswire/ — Field Medical, Inc. (Field Medical), an emerging leader in cardiac catheter ablation, announced today that it has closed its oversubscribed seed round with investments totaling $14M. The convertible note funding was led by private investors who were joined by multiple strategic investors. This financing will support preclinical-to-clinical […]
Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)
CAMBRIDGE, Mass., September 18, 2023 (BUSINESS WIRE)– Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences, announced today that the AZALEA-TIMI 71 Phase 2 study in 1,287 patients with atrial fibrillation at moderate-to-high risk of stroke, met its primary endpoint. The […]
SmartCardia Receives FDA Clearance for its 14-Day 7-Lead ECG Real-Time Patch and Cloud Platform
LAUSANNE, Switzerland, Sept. 15, 2023 /PRNewswire/ — SmartCardia has received FDA clearance for its 7-lead real-time ECG monitoring patch and cloud platform. SmartCardia’s 7L patch is easy-to-wear, cable-free, waterproof and can be used for continuous monitoring for up to 14 days. SmartCardia 7L Patch SmartCardia Cloud Dashboard “SmartCardia’s 7L patch and cloud platform […]
JenaValve Appoints Shlomi Nachman to Board of Directors
IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Shlomi Nachman, experienced cardiovascular industry executive, to its Board of Directors. Mr. Nachman has over 25 years of experience in the medical device […]
AngioDynamics to Report Fiscal 2024 First Quarter Financial Results on October 4, 2023
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the first quarter of fiscal year […]
Us2.ai Partners with Leading Academic Medical Center to Collaborate on AI-Enabled Echocardiography Software
SINGAPORE–(BUSINESS WIRE)–Us2.ai, a Singapore-based MedTech firm, has partnered with Duke University to co-develop and commercialize AI tools for echocardiography, to enable earlier detection, improved diagnosis and more efficient management of heart disease. “This advances Duke University’s efforts in digitalising clinical trials” Tweet this In clinical practice, echocardiography is now firmly established as […]
Edgewise Therapeutics Begins Dosing First-in-Human Phase 1 Trial of EDG-7500, its Lead Clinical Candidate for Hypertrophic Cardiomyopathy (HCM) and Other Serious Diseases of Cardiac Diastolic Dysfunction
BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500. EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with HCM and other […]
Attune Medical’s ensoETM™ Granted FDA De Novo Marketing Authorization to Reduce the Likelihood of Ablation-related Esophageal Injury Resulting from Radiofrequency Cardiac Ablation Procedures
CHICAGO–(BUSINESS WIRE)–Attune Medical has been granted De Novo marketing authorization from the US Food and Drug Administration (FDA) for its ensoETM device to reduce the likelihood of ablation-related esophageal injury resulting from radiofrequency cardiac ablation procedures. “Our lab has published studies showing a 30 percent reduction in procedure time and a 14 percent […]



